Management of Incidentally Discovered Pancreatic Cysts
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the natural history of pancreatic cysts and to determine if these cysts can be effectively treated with a less invasive therapy (ethanol injection vs periodic imaging) rather than surgical resection
| Condition | Intervention | Phase |
|---|---|---|
|
Pancreatic Cyst |
Other: Ethanol lavage |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Prospective Study of the Management of Incidentally Discovered Pancreatic Cysts |
- Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)? [ Time Frame: 3 years ] [ Designated as safety issue: No ]
| Enrollment: | 0 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: A
Observation of pancreatic cysts
|
|
|
Experimental: B
Ethanol lavage of pancreatic cysts
|
Other: Ethanol lavage
Ethanol lavage of pancreatic cysts.
|
Detailed Description:
The appropriate management of patients with cystic lesions of the pancreas is controversial. The identification of small asymptomatic pancreatic cysts is increasing due to an improvement in the quality of radiologic imaging and the frequency that imaging is obtained. However, the natural history of these lesions is unknown1. The current consensus guidelines established at the International Consensus Conference in Sendai, Japan in 2005 suggest that branch chain IPMNs and mucinous cystic neoplasms that cause no symptoms, measure <3cm, and have no nodules can be observed with periodic imaging. However, the time course of these pre malignant mucinous lesions, intraductal papillary mucinous neoplasms (IPMN) or mucinous cystadenomas, from benign to malignant has not been determined. Due to the unknown natural history, and diagnostic uncertainty, some authors have recommended routine resection2, 3. Resection, despite improvements in surgical outcomes after pancreatectomy at high volume centers, carries a mortality and morbidity of 1-6% and 35-51%, respectively4-6. More recently studies are reporting a more selective approach to avoid the risk of operation in patients with benign lesions7. Improved radiographic and endoscopic studies have been able to identify some lesions with increased malignant potential8, 9. Thus, most patients will undergo pancreas specific radiologic imaging and endoscopic ultrasound with cyst aspiration. Since the natural history of cystic lesions is poorly understood no clear guidelines for surgical resection have been established. Some of the cysts will grow over time, with an increase in the cumulative risk of malignancy. Therefore, the therapeutic alternatives are to wait and watch for a change in the cyst morphology or to treat preemptively, which has been restricted to surgical resection. Based on the pilot study performed by Dr. William Brugge, at Massachusetts General Hospital, ethanol lavage of pancreatic cysts is safe and will result in a decrease in cyst diameter in 61% of patients. Additionally, if patients elect to not be treated preemptively it is unclear how to best follow these patients in terms of the type and the frequency of follow up studies.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Cyst between 1-3cm
- No evidence of a mural nodule, solid component, or septations in the cyst
- For patients with multiple cysts, the largest will be evaluated
Exclusion Criteria:
- Any imaging or cytology concerning for malignancy
- Pancreatic Pseudocyst
- Gross Cyst >3cm as measured on MRCP
- Clinically active pancreatitis or serum amylase or lipase >3x upper limit of normal
- Coagulopathy (INR>1.5, PTT>100, Platelets<50K)
- Inability to tolerate conscious sedation and endoscopy
- Rated ASA IV or greater
- Prior EUS and aspiration of the pancreatic cyst
- Breast feeding
- Pregnancy
Contacts and Locations| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | Cristina R Ferrone, MD | Massachusetts General Hospital |
More Information
Publications:
| Responsible Party: | Cristina R. Ferrone, MD, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00550108 History of Changes |
| Other Study ID Numbers: | 2007-P-000420 |
| Study First Received: | October 24, 2007 |
| Last Updated: | June 23, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
pancreatic cyst ethanol injection |
Additional relevant MeSH terms:
|
Cysts Pancreatic Cyst Neoplasms Pathological Conditions, Anatomical Pancreatic Diseases Digestive System Diseases Ethanol |
Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Central Nervous System Depressants Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 21, 2013